Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526778 | 1.00 | PIM1 (0.64) | PIM1KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3499199 | 0.86 | PIM1 (0.59) | PIM1KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL16595303 | 0.86 | NPC1 (0.56) | PIM1KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2706216 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1CYP1A2CYP2C9GPR35 | |
| SCHEMBL29994222 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1CYP1A2CYP2C9GPR35 | |
| SCHEMBL3613922 | 0.85 | MAOB (0.63) | KDM4EALDH1A1CYP1A2CYP2C9GPR35 | |
| SCHEMBL5601015 | 0.85 | ALDH1A1 (0.58) | PIM1KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL6894785 | 0.84 | KDM4E (0.67) | KDM4EALDH1A1CYP1A2CYP2C9GPR35 | |
| SCHEMBL6239408 | 0.82 | HDAC3 (0.60) | KDM4EALDH1A1CYP1A2CYP2C9GPR35 | |
| SCHEMBL30629235 | 0.82 | NPC1 (0.69) | KDM4EALDH1A1CYP1A2CYP2C9GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110078720-A | Halogenated benzofuran-coumarin derivative and its preparing the application in fouling resistance agent | 扬州工业职业技术学院 | 2019-08-02 | — | — | CN | claimed |
| CN-106397377-B | The method of fluorine on a kind of electron rich five-ring heterocycles acid and its derivative decarboxylation | 中南大学 | 2019-04-05 | — | — | CN | claimed |
| CN-106397377-A | Electron-rich five-membered heterocyclic acid and method for decarboxylation and fluorination of derivative thereof | 中南大学 | 2017-02-15 | — | — | CN | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | claimed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| WO-2010012396-A1 | 5,6 SUBSTITUTED BENZAMIDE DERIVATIVES AS MODULATORS OF THE EP<SB>2 </SB>RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | claimed |
| EP-2149552-A1 | 5,6 substituted benzamide derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | PIM1 2992/4885KDM4E 3961/4885ALDH1A1 642/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | PIM1 4454/4885KDM4E 4309/4885ALDH1A1 527/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | PIM1 4763/4885KDM4E 3048/4885ALDH1A1 834/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | PIM1 3365/4885KDM4E 3285/4885ALDH1A1 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.